Nasus Pharma
Nasus Pharma develops powder-based intranasal therapies for acute, life-threatening medical emergencies. The company focuses on rapid and predictable drug absorption using a scalable proprietary platform. Their pipeline includes clinical-stage candidates for anaphylaxis, opioid overdose, and chemotherapy-induced nausea, emphasizing needle-free, stable, and portable drug delivery alternatives backed by clinical data. Nasus Pharma's mission is to address urgent medical needs through innovative intranasal formulations that offer faster onset and greater convenience than traditional injectables.
Industries
N/A
Patents
Products
Powder-based intranasal naloxone formulation designed for rapid opioid overdose reversal, achieving faster and higher systemic drug levels than standard liquid sprays. Completed pivotal phase 3 clinical study.
Powder-based intranasal epinephrine for treatment of anaphylaxis, providing rapid absorption, predictable pharmacokinetics, and improved patient convenience compared to injectable alternatives. Currently in phase 2 clinical development.
Proprietary powder formulation of ondansetron for intranasal administration, developed for chemotherapy and post-operative induced nausea and vomiting. Preclinical studies show pharmacokinetics comparable to intravenous administration.
Preclinical intranasal powder candidates targeting metabolic and cardiovascular emergencies, leveraging the same proprietary platform for rapid and reliable delivery.
Powder-based intranasal naloxone formulation designed for rapid opioid overdose reversal, achieving faster and higher systemic drug levels than standard liquid sprays. Completed pivotal phase 3 clinical study.
Powder-based intranasal epinephrine for treatment of anaphylaxis, providing rapid absorption, predictable pharmacokinetics, and improved patient convenience compared to injectable alternatives. Currently in phase 2 clinical development.
Proprietary powder formulation of ondansetron for intranasal administration, developed for chemotherapy and post-operative induced nausea and vomiting. Preclinical studies show pharmacokinetics comparable to intravenous administration.
Preclinical intranasal powder candidates targeting metabolic and cardiovascular emergencies, leveraging the same proprietary platform for rapid and reliable delivery.
Expertise Areas
- Intranasal drug delivery
- Emergency medicine therapeutics
- Powder formulation technology
- Preclinical and clinical pharmacology
Key Technologies
- Powder-based intranasal delivery
- Particle engineering for dry powder delivery
- Spray drying technology
- Nasal drug absorption optimization
Key People
Chief Executive Officer, Board Member
Co-founder, Board Member, Chief Development Officer
Executive Vice President and Chief Financial Officer
Vice President, Research and Development and Clinical Development
Vice President, CMC
Director of Product Development
Chief Executive Officer, Board Member
Co-founder, Board Member, Chief Development Officer
Executive Vice President and Chief Financial Officer
Vice President, Research and Development and Clinical Development
Vice President, CMC
Director of Product Development
News & Updates
Scientific poster comparing absorption of powder versus liquid nasal epinephrine for anaphylaxis.
Study on freeze-thaw stability of intranasal epinephrine powder spray.
Clinical study on dosing for first-in-class intranasal epinephrine spray.
Analysis of two clinical trials of long-shelf-life intranasal powder-spray epinephrine.
Discussion on future use of dry powder, needle-free, intranasal epinephrine for anaphylaxis treatment.
Study on the efficacy of a new fast acting naloxone powder nasal spray.
Scientific poster comparing absorption of powder versus liquid nasal epinephrine for anaphylaxis.
Study on freeze-thaw stability of intranasal epinephrine powder spray.
Clinical study on dosing for first-in-class intranasal epinephrine spray.
Analysis of two clinical trials of long-shelf-life intranasal powder-spray epinephrine.
Discussion on future use of dry powder, needle-free, intranasal epinephrine for anaphylaxis treatment.
Study on the efficacy of a new fast acting naloxone powder nasal spray.